Imaging With a New Agent That Finds a Cancer Protein Called HER2

• Status: Completed
• Trial end date: 2018-04-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Pertuzumab

Criteria

Inclusion Criteria:

• Age 21 years or greater

• Any biopsy proven HER2-positive malignancy. ASCO guidelines will be used to define HER2-positivity for breast cancer. Similar guidelines will be used for other cancer types as appropriate.

• At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment

• ECOG performance of 0-2

Exclusion Criteria:

• Life expectancy < 3 months

• Pregnancy or lactation

• Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.